Islet cell transplantation for the treatment of diabetes mellitus

Expert Opinion on Biological Therapy

Volumn 1, Issue 1, 2001, Pages 109-119

  Kendall Jr , William F ^a   Collins, Bradley H ^a   Opara, Emmanuel C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Diabetes; Islet cell transplantation; Islet cells; Microencapsiilation; Pancreas transplantation; Xenotransplantation; cells

Indexed keywords

INSULIN; LAXATIVE; SODIUM SULFATE; SULFATE;

ANIMAL; CELL TRANSPLANTATION; DIABETES MELLITUS; HUMAN; METHODOLOGY; PANCREAS ISLET; PHYSIOLOGY; REVIEW; TIME; XENOGRAFT;

ANIMAL; CATHARTICS; CELL TRANSPLANTATION; DIABETES MELLITUS; HUMAN; INSULIN; ISLETS OF LANGERHANS; SULFATES; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0035226718     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.1.109     Document Type: Article

References (104)

1. CHUDLEY AE: Genetic landmarks through philately - a brief history of diabetes mellitus. Clin. Genet. (1999) 55 (4):231-233.
2. ONAT T: The history of endocrinology in philately. J. Pediatr. Endocrinol. Metabol. (1997) 10:371-377.
3. SAFRAN MA, VINICOR F: The war against diabetes. How will we know if we are winning? Diabetes Care (1999) 3:508-516.
4. SEIDELL JC: Obesity, insulin resistance and diabetes - a worldwide epidemic. Br.J.Nntr. (2000) 83(Suppl. 1):5-8.
5. KING H, AUBERT RE, HERMAN WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care (1998) 21(9):1414-1431. This article presents a global overview on the impact of diabetes.
6. HARRIS MI, FLEGAL KM, COWIE CC: Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. Diabetes Care (1998) 21:518-524.
7. HARRIS MI: Diabetes in America:epideniiology and scope of the problem. Diabetes Care (1998) 21(Suppl.3):C11-14.
8. AMERICA DIABETES ASSOCIATION: Economic consequences of diabetes in the US hi 1997. Diabetes Oin?(1998) 21(2):296-309
9. JONSSON B: The economic impact of diabetes. Diabetes Care (1998) 21(Suppl. 3):C7-C10.
10. OPARA EC: The therapeutic potential of islet cell transplant in the treatment of diabetes. Exp. Opin. Inrest. Drugs. (1998) 7(5):785-795.
11. GAV1N JR 3rd: New classification and diagnostic criteria for diabetes mcllitus. Clinical Cornerstone. (1998) 1(3):1-12.
12. BACH JF: Insulin-dependent diabetes mcllitus is an autoimmune disease. Enclocr. Rev. (199-4) 15:516-542.
13. RABINOVITCH A, SUAREZ-PINZON WL: Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem. Pbarmacol. (1998) 55(8):1139-1149.
14. MAURICIO D, MANDRUP-PAULSEN T: Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes (1998) 47(10):1537-1543.
15. KAHN R: Type 2 diabetes in children and adolescents. Pediatrics (2000) 105(3):671-680.
16. DEFRONZO RA: The triumvirate: B-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes (1988) 37:667-687.
17. OPARA EC, PETRO A, TEVRIZIAN A, FEINGLOS MM, SUKWIT RS: L-Glutamine supplementation of a high-fat diet reduces body weight and attenuates hyperglycemia and hypcrinsulinemia inC57Bl/6j mice. J Nutr. (1996) 126:273-279.
18. STORLIEN LH, BAUR LA, KRIKETOS AD et al.: Dietary fats and insulin action. Diabetologia (1996) 39:621-631.
19. HARRIS MI: Descriptive epidemiology. In: Diabetes in America (2nd Edition). NIDDK, National Institutes of Health, Bethesda, MD, USA (1995).
20. AKBARI CM, LO GERFO FW: Diabetes and peripheral vascular disease./ Vase. Surg. (1999) 30(2):373-384.
21. WILLIAMS SB, CUSCO JA, RODDY M, JOHNSTONE MY, CREAGER MA: Impaired nitric oxide-mediated vasodilation in patients with non-insulin -dependent diabetes mellitus.J.Am. Coll. Canliol.(1996) 27:567-574.
22. JOHNSTONE MT, CREAGER SJ, SCALES KM, CUSCO JA, LEE BK, CREAGER MA: Impaired endothelium dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. (1993) 88:2510-2516.
23. KOYA D, KING GL: Protein Kinase C activation and the development of diabetic complications. Diabetes. (1998) 47(6):859-866.
24. SCHMIDT AM, YAN SD, WAUTIER JL, STERN D: Activation of receptor for advanced gtycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. (1999) 84(5):489-497.
25. OPARA EC, ABDEL-RAHMAN E, SOLIMAN S et al.: Depiction of total antioxidant capacity in Type 2 diabetes. Metabolism (1999) 48(11):1414-1417.
26. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Ar. Engl.J. Med. (1993) 329(14):977-986. This study unequivocally showed that strict glycaemic control had significant delay effects on the onset and progression of diabetic complications.
27. KELLY WD, LILLEHEIRC, MERKEL FK, IDEZUKI Y, GOETZ FC: Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery (.1961) 61:827-837.
28. BOREL JF, FEURER C, GUBLER HU, STAHELIN H: Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions (1976) 6(4):468-475.
29. SOLLINGER HW, ODORICO JS, KNECHTLE SJ, D'ALESSANDRO AM, KALAYOGLU M, PIRSCH JD: Experience with 500 simultaneous pancreas-kidney transplants. Ann. Surg. (1998) 228(3):284-296.
30. REICHARD P, NILSSON BY, ROSENQV1ST U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl.J. Med. (1993) 329(5):304-309. This study clearly showed that strict glycaemic control can prevent some of of the complications of diabetes.
31. SOLDERS G, TYDEN G, PERSSON A, GROTH CG: Improvement of nerve conduction in diabetic neuropathy: a follow-up study 4 yr after combined pancreatic and renal transplantation. Diabetes (1992) 41:946-951. This study shows that strict hyperglycaemic control can reverse some of the complications of diabetes.
32. BILOUS RW, MAUER SM, SUTHERLAND DER, NAJARIAN JS, GOETZ FC, STEFFES MW: The effect of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N. Engl.J. Med (1989) 321(2):80-85. This study clearly showed that strict glycaemic control can prevent some of the complications of diabetes.
33. HATHAWAY DK, ABELL T, CARDOSO S, HARTWIG MS, GEBELY SE, GABER AO: Improvement in autonomie and gastric function following pancreas-kidney versus kidney alone transplantation and the correlation with quality of life. Transplantation (1994) 57(6):816-822.
34. CALDARA R, LA ROCCA E, MAFFI P, SECCHI A: Effect of pancreas transplantation on late complications of diabetes and metabolic effects of pancreas and islet transplantation. J. Pediatr. Endocrinol. Metab. (1999) 12:777-787.
35. ORLOFF MJ, GREENLEAF GE, URBAN P, GIRARD B: Lifelong reversal of the metabolic abnormalities of advanced diabetes in rats by whole-pancreas transplantation. Transplantation (1986) 41(5):556-564.
36. IDO Y, VINDIGNI A, CHANG K et al.: Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science (1997) 277(5325)063-566. This study shows for the first time that c-peptide which was thought not to have any significant biologic function may play a role in prevention of diabetic complications.
37. BRUNICARDI FC, MÜLLEN Y: Issues in clinical islet transplantation. Pancreas (199-4) 9(3):281-290.
38. DERTUZZI F, SECCHI A, ALDRIGHETTI L, NANO R, POZZA G, DI CARLO V: Islet transplantation in diabetic patients. J. Pediatr. Endocrinol. Metabol. (1999) 12:771-775.
39. FARNEY AC, NAJARIAN JS, NAKLEH RE et al.: Autotransplantation of dispersed pancreatic islet tissue combined with total or near total pancreatectomy for treatment of chronic pancreatitis. Surgery (1991) 210:427-439.
40. ANGEUCO MC, ALEJANDRO R, NERY J et ah Transplantation of islets of langcrhans in patients with insulin requiring diabetes mcllitus undergoing orthotopic liver transplantation./ Mol. Meci. (1999) 77:144-147.
41. OBERHOLZER J, TRIPONEZ F, MAGE R étal.: Human islet transplantation: Lessons from 13 autologous and 13 allogcncic transplantations. Transplantation (2000) 69(6):1115-1123.
42. RILO HL, CARROLL PB, TZAKIS A et aL- Insulin independence for 58 months following pancreatic islet cell transplantation in a patient undergoing upper abdominal exenteration. Transplant Proc. (1995) 27(6):3l64-3l65.
43. WARNOCK GL, KNETEMAN NM, RYAN EA, RABINOVITCH A, RAJOTTE RV: Long-term follow-up after transplantation of insulin producing pancreatic islets into patients with Type 1 (insulin-dependent) diabetes mcllihis. Diabetalogia. (1992) 35:89-95.
44. ALEJANDRO R, LEHMANN R, RICORDIC et al.: Long-term function (6 years) of islet allografts in Type 1 diabetes. Diabetes (1997) 46(12):1983-1989. First study showing long-term survival of transplanted pancreatic islets.
45. FED ERLIN KF, BRETZEL RG: Achievements in 20 years of islet transplantation research. Transplant Proc. (1986) 18(6):1809-1813.
46. SHAPIRO AMJ, LAKEY JRT, RYAN EA et al.: Islet transplantation in seven patients with Type 1 diabetes mcllitus using a glucocorticoid-free immunosuppressive regimen. N. Engl.J. MedUOOO) 343(4);230-238. Study showing reproducibility and efficacy of pancreatic islet transplantation. Also indicative of ongoing change in current approach to immunosuppression.
47. KENYON NS, RANUNCULI A, MASETTI M, CHATZIPETROU M, RICORDI C: Islet transplantation: present and future perspectives. Diabetes Metab. Reu. (1998) 14(4):303-313.
48. STRATTA RJ: Review of immunosuppressive usage in pancreas transplantation. Clin. Transplant (1999) 13(1 Pt 1):1-12.
49. BUTLER D: PDA warns on primate xenotransplants. Nature (1999) 398:549.
50. GALIU U: Evolution of al, 3 Galactosyltransferase and of the a-gal epitope. In: Subcelhilar Biochemistry, (Volume 32): a-gal and Anti-Gal. Kluwer Academic/Plenum Publishers, New York, USA (1999).
51. NOWAK R: Pig transplants offer hope in diabetes. Science (1994) 266:1323.
52. DOBSON R: Cloning of pigs bring xcnotransplants closer. Br. Med. J. (2000) 320(7238):826.
53. LOGAN JS, SHARMA A: Potential use of genetically modified pigs as organ donors for transplantation into humans. Clin. Exp. Pbramacol. Physiol. (1999) 26:1020-1025.
54. COZZI E, WHITE DJ: The generation of transgenic pigs as potential organ donors for humans. Nature Ated. (1995) l(9):964-966.
55. HENEINE W, TIBELL A, SWITZER WM et al.: No evidence of infection with porcine endogenous rctrovirus in recipients of porcine islet-cell xenografts. Lancet (1998) 352:695-699.
56. PARADIS K, LANGFORD G, LONG Z et al: Search for cross-species transmission of porcine endogenous rctrovirus in patients treated with living pig tissue. Science (1999) 285(5431):1236-1241. In 160 patients, with longest follow-up approximately 12 years, there was no evidence of retroviral transmission.
57. CHAR1 RS, COLLINS BH, MAGEE JC et al:. Brief report: treatment of hepatic failure with ex-vivo pig-liver perfusion followed by liver transplantation. A'. Engl.J. Meet. (1994) 33K4):234-237.
58. WEIR GC, BONNER-WEIR S: Scientific and political impediments to successful islet transplantation. Diabetes (1997) 46(8):1247-1256.
59. MCKENZIE IFC, KOULMANDA M, MANDEL T, SANDRIN MS: Expression of Gal a (1,3) Gal by porcine islet cells and its relevance to xenotransplantation. Xenotransplantation (1995) 2:139-142 Isolated adult pig islets may not have Gal a (1,3) Gal epitope.
60. TACKE SJ, KURTH R, DENKER J: Porcine endogenous retroviruses inhibit human immune cell function: risk for xenotransplantation? Virology (2000) 268:87-93.
61. CHING CD, HARLAND RC, COLLINS BH, KENDALL W, HOBBS H, OPARA EC: A reliable method for isolation of viable porcine islets. Arch. Surg. (In Press). Highly reproducible procedure to isolate intact rather than fragmented porcine islets.
62. CHARLES K, HARLAND RC, CHING D, OPARA EC: Storage and microencapsulation of islets for transplantation. Cell Transplant. (2000) 9:33-38. Shows procedure with tremendous impact for routine use of islet cell transplants.
63. CRETIN N, BUHLER L, FOURNIER B et ah. Human islet allotransplantation: world experience and current status. Dig. Surg. (1998) 15:656-662.
64. KOJIMA Y, NAKAGAWARA G, IMABORI T, TAKEYAMA S, NOTE M, MIYAZAKI I: Experimental studies on cryopreservation combined with the cultural process of isolated rat pancreatic islets. Jpn. J. Surg. (1982) 12:463-467
65. SANDLER S, ANDERSSON A. The significance of culture for successful cryopreservation of isolated pancreatic islets of langerhans. Ctyvbiotog)' (1984) 21:503-510.
66. TAYLOR MJ, BANK HL. Function of lymphocytes and macrophages after cryoprescrvation by procedures for pancreatic islets: potential for reducing tissue inununogenicity. Crjutoo/ogy(1988) 25:1-17.
67. TAYLOR MJ, BANK HL, BENTON MJ. Selective destruction of leukocytes by freezing as a potential means of modulating tissue immunogenicity: membrane Integrity of lymphocytes and macrophages. Cryobio/ogy(1987) 24:91-102.
68. FOREMAN J, MORIYA H, TAYLOR MJ. Effect of cooling and its interaction with pre-freeze and post-thaw tissue culture on the in vitro and in vivo function of cryopreserved pancreatic islets. Tmnspl. Int. (1993) 6:191-200.
69. BAILEY CJ, DA VIES EL, DOCHERTY K: Prospects for insulin delivery by ex-vivo somatic cell gene therapy. J. Mol. Med. (1999) 77:244-249-
70. TIEDGE M, ELSNER M, MCCLENAGHAN NH et al.: Engineering of a glucose-responsive surrogate cell for insulin replacement therapy of experimental insulindependent diabetes. Hum. Genener.(3.(XX>) 11:403-414.
71. BROWNLEE M: Generation of non-immune islet cells using genetic engineering. J. Mol. Med. (1999) 77:230-234.
72. SORIA B, RÖCHE E, BERNA' G, LEO'N-QUINTO T, REIG JA, MARTI'N F: Insulin -secreting cells derived from embryonic stem cells normalize glycemia in streptozocin-induced diabetic mice. Diabetes (2000) 49(2):157-162. Suggests newer options for source of islets.
73. BONNERAVEIR S, TANEJA M, WEIR GC et ni.: In-vitro cultivation of human islets from expanded ductal tissue. Proc. Natl.Acad. Sci. USA (2000) 97(14):7999-8004. Suggests newer options for source of islets.
74. SLAVIN S, PRIGHOZINA T, GUREVITCH O et al..- New approaches for control of anti-self reactivity in Type 1 diabetes mcllitus and transplantation of pancreatic islets./ Mol. Med. (1999) 77:223-225.
75. RAMIYA VK, MARAIST M, ARFORS KE, SCHATZ DA, PECK AB, CORNELIUS JG: Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nature Med. (2000) 6(3):278-282.
76. BACH FH, ROBSON SC, WRIGHTON CJ, STUHLMEIER K, FERRAN C, WINKLER H: Genetic engineering of endothclial cells to ameliorate xcnograft rejection. Clin. Transplant. (1996) 10(0:124-127.
77. EFRAT S: Genetically engineered pancreatic β-cell lines for cell therapy of diabetes. Ann. NYAcaci. Sci. (1999) 875:286-293.
78. MCCLENAGHAN NH, FLATT PR: Engineering cultured insulin-secreting pancreatic β-cell lines. J Mol. Med. (1999) 77:235-243.
79. WEKERLE T, KURTZ J, HIROSHI I et al. Allogencic bone marrow transplantation with co-stimulatory blockade induces macrochimcrism and tolerance without cytoreductive host treatment. Nature Med. (2000)
80. LARSEN CP, EIAVOOD ET, ALEXANDER DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD 28 pathways. A'<7/H;-
81. KIRK AD, BURKLY LC, BATTY DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Meet. (1999) 5(6):686-93.
82. Pancreatic Islet Transplantation: Volume III, Immtinoisolation of Pancreatic Islets. Lanza RP, Chick WL (Eds.), RG Landes Co., Georgetown, USA (1994).
83. RICORDI C: Recent advances in alginatc-based microcapsules. In: Pancreatic Islet Cell Transplantation RG Landes, Georgetown, USA (1992) 191:206.
84. CHANG TMS: Semipermeable microcapsulcs. Science (1964) 146:524-525.
85. LIM F, SUN AM: Microencapsulatcd islets as a bioartificial endocrine pancreas. Science (1980) 210:908-910. First description of microencapsulation as a procedure for immunoisolation of islets.
86. Pancreatic Islet Transplantation: Volume III, Immunoisolation of Pancreatic Islets. Lanza RP, Chick WL (Eds.), RG Landes Co., Georgetown, USA (1994) 81:94.
87. ESPEVIK T, OTTERLEI M, SKJAK-BRAEK G, RYAN L, WRIGHT SD, SUNDAN A. The involvement of CD 14 in stimulation of cytokine production by uronic acid polymers. Etir.J. Immunol. (1993) 23:255-261.
88. SOON-SHIONG P, FELDMAN E, NELSON R et al. Long-term reversal of diabetes by injection of immunoprotccted islands. Proc. Ai?/J. Acad. Sci. USA (1993) 90(12):5843-5847.
89. KULSENG B, THU B, ESPEVIK T, SKJAK-BRAEK G. Alginate polylysine microcapsules as immune barrier: permeability of cytokines and immunoglobulins over the capsule membrane. Cell Transplantation (1997) 6(4):387-394.
90. CLAYTON HA, JAMES RFL, LONDON NJM: Islet microencapsulation: a review. Acta Diabetol. (1993) 30(4):181-189.
91. CAPPAI A, PETRUZZO P, RUIU G et al.: Evaluation of new small barium alginatc microcapsules. Int. .J. Artif. Organs. (1995) 18(2):96-102.
92. GARFINKEL MR, HARLAND RC, OPARA EC: Optimization of the microencapsulated islet for transplantation. J. Surg. Res. (1998) 76:7-10. Shows that chelation of inner core increases efficacy of microencapsulation.
93. SMIDSROD O, SKJAK-BRAEK G: Alginate as immobilization matrix for cells. Trends Biotecbnol. ( 1990) 8(3):71 -78.
94. DARRABIE MD, FREEMAN BK, KENDALL JR WF, HOBBS HA, OPARA EC: Durability of sodium sulfatc-trcatcd polylysinc-alginate microcapsulcs. J Biomcd. Mater. Res. (In Press).
95. ZIMMERMAN U, MIMIETZ S, ZIMMERMAN H et al.: Hydrogcl-bascd non-autologous cell and tissue therapy. Bio. Techniques (2000) 29:564-581. Excellent review showing different options for immunoisolation of islets.
96. DE VOS P, DE HAAN B, PATER J, VAN SCHILFGAARDE R: Association between capsule diameter, adequacy of encapsulation and survival of microencapsulated rat islet allografts. Transplantation (1996) 62(7):893-899.
97. CHICHEPORTICHE D, REACH G: In vitro kinetics of insulin release by microencapsulated rat islets: effect of the size of the microcapsules. Diabetologia (1988) 31:54-57.
98. SCHREZENMEIERJ, KIRCHGESSNERJ, GERO L, KUNZ LA, BEYERJ, MUELLER-KLIESER W: Effect of microencapsulation on oxygen distribution in islets organs. Transplantation (1994) 57:1308-1314.
99. DE VOS P, DE HAAN BJ, WOLTERS GHJ, STRUBBE JH, VAN SCHILFGAARDE R: Improved biocompatibility but limited graft survival after purification of alginatc for microencapsulation of pancreatic islets. Diabetologia (1997) 40:262-270.
100. VAN SCHILFGAARDE R, DE VOS P: Factors influencing the properties and performance of microcapsulcs for immunoprotection of pancreatic islets. J. Mol. Med. (1999) 77:199-205.
101. COLLINS BH, PIRSCH JD, BECKER YT et al.- Long-term results of liver transplantation in patients 60 years of age and older. Transplantation (2000) 70(5):780-783.
102. GOOSEN MFA, O'SHEA GM, GHARAPETIAN HM, CHOU S: Optimization of microencapsulation parameters: semipermeable microcapsules as a bioartificial pancreas. Blotecbnol. Bioeng. (1985) 27:146-150.
103. BRANDHORST H, BRANDHORST D, HERING BJ, BRETZEL RG: Significant progress in porcine islet mass isolation utilizing libcrasc HI for enzymatic low-temperature pancreas digestion. Transplantation (1999) 68(3):325-326.
104. RAJOTTE RV: Islet cryopreservation protocols. Ann. N Y Acad. Sel. (1999) 875:200-207.